AUSTRALIAN PRODUCT INFORMATION – BORTEZOMIB-TEVA (BORTEZOMIB) POWDER FOR INJECTION 1 NAME OF THE MEDICINE 2 & 3 QUALITATIV
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma | Leukemia
Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms | BMC Cancer | Full Text
Bortez Teva | Medic
Millennium Pharmaceuticals, Inc. v. Sandoz Inc. (Fed. Cir. 2017) | McDonnell Boehnen Hulbert & Berghoff LLP - JDSupra
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US | SpringerLink
Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma - Kubiczkova - 2014 - Journal of Cellular and Molecular Medicine - Wiley Online Library
View of Stability of Generic Formulations of Bortezomib 1.0 and 2.5 mg/mL in Vials and Syringes Stored at 4°C and Room Temperature (23°C or 25°C) | Canadian Journal of Hospital Pharmacy
PRODUCT CATALOGUE
Summary Public Assessment Report Generics Bortezomib Teva 1 mg and 3.5 mg powder for solution for injection Bortezomib HR/H/0102
Bortezomib Teva 3.5 mg | Medic
Population-based meta-analysis of bortezomib exposure–response relationships in multiple myeloma patients | Request PDF
Bortezomib (PS-341) | Proteasome Inhibitor | MedChemExpress
Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms | BMC Cancer | Full Text
Bortezomib (PS-341) | Proteasome Inhibitor | MedChemExpress
Download bortezomib images for free
Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations
Bortezomib (PS-341) | Proteasome Inhibitor | MedChemExpress
Bortezomib 3,5 mg | Laboratorio Chile | Teva
With appeals court win, Takeda scores blockbuster Velcade patent reprieve till 2022 | Fierce Pharma
Dose-dependent immunomodulatory effects of bortezomib in experimental autoimmune neuritis
Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma - Kubiczkova - 2014 - Journal of Cellular and Molecular Medicine - Wiley Online Library
Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma | Blood Cancer Journal
